Literature DB >> 20958793

Worldwide diffusion of FVII Arg304Gln coagulation defect (FVII Padua).

Antonio Girolami1, Giulia Berti de Marinis, Emanuela Bonamigo, Emanuele Allemand.   

Abstract

FVII Padua is a Type 2 defect owing to an Arg304Gln substitution in exon 8. The defect was originally discovered in an isolated valley in northeastern Italy. Subsequently, it was described in several other countries of the Mediterranean basin and Middle East. Recently, several proven or suspected cases have been described among Afro-Americans in the USA. This study has demonstrated the existence of at least a two-founder effect for this FVII abnormality, Mediterranean countries, and USA Afro-Americans. Patients are usually asymptomatic or only paucisymptomatic. The defect is characterized by low FVII activity when rabbit brain thromboplastins are used in the assay system. On the contrary, FVII levels are normal when ox-brain thromboplastins are used. FVII antigen is always normal.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20958793     DOI: 10.1111/j.1600-0609.2010.01544.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

Review 1.  Congenital FVII deficiency and thrombotic events after replacement therapy.

Authors:  Antonio Girolami; Irene Bertozzi; Ignazio Rigoni; Rodolfo Muzzolon; Silvia Vettore
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

Review 2.  Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy.

Authors:  Mariasanta Napolitano; Sergio Siragusa; Guglielmo Mariani
Journal:  J Clin Med       Date:  2017-03-28       Impact factor: 4.241

3.  Identification of genetic defects underlying FVII deficiency in 10 patients belonging to eight unrelated families of the North provinces from Tunisia.

Authors:  Hejer Elmahmoudi; Fatma Ben-Lakhal; Wijden Elborji; Asma Jlizi; Kaouther Zahra; Rim Sassi; Moez Zorgan; Balkis Meddeb; Amel Elgaaied Ben Ammar; Emna Gouider
Journal:  Diagn Pathol       Date:  2012-08-08       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.